<DOC>
	<DOCNO>NCT02826681</DOCNO>
	<brief_summary>Treatment Phase I II Primary Objective : To evaluate efficacy safety FCM ( 750 mg dose x 2 ) treatment Restless Legs Syndrome ( RLS ) patient iron-deficiency anemia ( IDA ) . Long-Term Extension Phase III Primary Objective : To evaluate duration effect prior FCM treatment determine effectiveness iron repletion FCM RLS symptom worsen reoccur .</brief_summary>
	<brief_title>Randomized , Placebo-controlled Trial Ferric Carboxymaltose RLS Patients With Iron-deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Male female subject ≥18 year age able give inform consent . 2 . Confirmed diagnosis RLS base CambridgeHopkins Diagnostic Questionnaire ( CHDQ ) HopkinsHening Telephone Diagnostic Interview ( HDTI ) . 3 . IRLSS score ≥15 plus RLS symptoms least 3 month currently occur ≥2 night per week . 4 . Irondeficiency anemia define Hgb &lt; 12 g/dl ferritin &lt; 20 ng/mL , ferritin &lt; 100 TSAT &lt; 18 % . 5 . Subjects sleep medication must stable dose least 6 month prior screen . 6 . Subjects risk pregnancy must negative pregnancy test screen practice acceptable form birth control , hysterectomy tubal ligation , otherwise incapable pregnancy , practice follow method contraception least one month prior study entry : hormonal contraceptive , spermicide barrier , intrauterine device , partner sterility . 1 . Disorders require treatment medication use RLS include : peripheral neuropathy neurodegenerative disorder ( i.e . Parkinson 's disease dementia ) . 2 . Current ( past 4 week ) use drug may cause treat RLS , e.g . opioids , calcium channel alpha2delta ligands , antidepressant , dopaminergic agonist antagonist , centrallyacting antihistamine . 3 . Any medical condition contraindicate MRI . 4 . Abnormal MRI baseline would confound outcome measure . 5 . Secondary RLS due neurological condition head trauma . 6 . History hemochromatosis , hemosiderosis , iron storage disorder iron metabolism disorder . 7 . Women clinically significant uterine bleeding ( &gt; 200 cc blood loss ) six month prior screen . 8 . Liver transaminase ( AST ALT ) great two time upper limit normal ( ULN ) . 9 . Known positive Hepatitis B antigen ( HBs Ag ) , unless positive test attribute receipt Hepatitis B vaccination childhood Hepatitis C viral antibody ( HCV ) evidence active hepatitis ( i.e. , AST/ALT great two time ULN ) . 10 . Known positive HIV1 HIV2 antibody ( antiHIV ) . 11 . Active acute know chronic infection . 12 . Rheumatoid arthritis symptom sign active inflammation . 13 . Pregnant lactating woman . 14 . Known hypersensitivity reaction component Injectafer® ( ferric carboxymaltose ) . 15 . Previously randomize Injectafer® ( FCM VIT45 ) clinical trial . 16 . Previous IV iron treatment RLS . 17 . Parenteral iron , erythropoiesis stimulating agent use blood transfusion within six week prior screen visit . 18 . Planned elective surgery study year . 19 . Chronic alcohol drug abuse within past six month . 20 . Any preexist laboratory abnormality , medical condition , disease , opinion Investigator , may cause subject unsuitable study place subject potential risk study , e.g . malignancy , uncontrolled hypertension , unstable ischemic heart disease , uncontrolled diabetes mellitus . 21 . Subject unwilling condition would prohibit comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>